ストックスクリーナーアプリを入手
20.02
2.01%
-0.41
アフターアワーズ：
20.40
0.38
+1.90%
Jasper Therapeutics Inc (JSPR) 最新ニュース
Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma (NASDAQ:JSPR) - Seeking Alpha
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate - Yahoo Finance
Is Jasper Therapeutics (JSPR) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Jasper Therapeutics' SWOT analysis: briquilimab's potential reshapes mast cell stock - Investing.com
Jasper Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewswire
Jasper Therapeutics to Present Briquilimab Updates at Major Healthcare Conferences | JSPR Stock News - StockTitan
Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $74.86 - MarketBeat
Stifel Initiates Coverage of Jasper Therapeutics (JSPR) with Buy Recommendation - MSN
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) News: Jasper Therapeutics, Inc. Reports Third Quarter 2024 Results - Defense World
Analysts Bullish on Jasper Therapeutics as Briquilimab Trials Show Promise - GuruFocus.com
Jasper Therapeutics Advances in Antibody Therapy Development - TipRanks
Jasper Therapeutics Inc (JSPR) Quarterly 10-Q Report - Quartzy
McDonald's Corp (MCD-N) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
TSX Oil and Gas EW Index (TXOE) QuotePress Release - The Globe and Mail
Nasdaq Other Finance Index (OFIN) QuotePress Release - The Globe and Mail
(JSPR) Long Term Investment Analysis - Stock Traders Daily
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire
Net Present Value Model: Jasper Therapeutics Inc’s Briquilimab - GlobalData
JSPRJasper Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Long Term Trading Analysis for (JSPR) - Stock Traders Daily
Jasper Therapeutics' SWOT analysis: briquilimab stock shows promise amid challenges - Investing.com
Jasper Therapeutics (NASDAQ:JSPR) Earns Buy Rating from HC Wainwright - MarketBeat
Jasper Therapeutics to Present Preclinical Briquilimab Data - GlobeNewswire
Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting - StockTitan
Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria - GlobeNewswire
Molina Healthcare (MOH) Set to Announce Earnings on Wednesday - Defense World
Analysts Set Rush Street Interactive, Inc. (NYSE:RSI) Target Price at $11.17 - Defense World
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $74.86 Consensus Target Price from Brokerages - MarketBeat
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - Citeline News & Insights
Jasper Therapeutics (NASDAQ:JSPR) Rating Reiterated by HC Wainwright - Defense World
Metagenomi (NASDAQ:MGX) Stock Rating Reaffirmed by HC Wainwright - Defense World
JMP Securities Reiterates Market Outperform Rating for Jasper Therapeutics (NASDAQ:JSPR) - Defense World
JMP Securities analysts initates a Mkt outperform rating for Jasper Therapeutics Inc (JSPR) - Knox Daily
Analysts review Ares Capital Corp’s rating - Knox Daily
Jasper Therapeutics shares keep buy rating with positive study results By Investing.com - Investing.com Canada
DoubleVerify Holdings Inc [DV] stock was sold by Allais Nicola T at the price of US$30365.0 - Knox Daily
When (JSPR) Moves Investors should Listen - Stock Traders Daily
Jasper Therapeutics Inc (JSPR) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Jasper gains 11% on data for briquilimab in urticaria (NASDAQ:JSPR) - Seeking Alpha
Jasper Therapeutics shares hold as Oppenheimer maintains $80 target By Investing.com - Investing.com Canada
Jasper Therapeutics shares hold as BTIG maintains $90 target By Investing.com - Investing.com UK
You Should Read This Analysis Before Investing in Jasper Therapeutics Inc (NASDAQ:JSPR) - US Post News
Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday? - Yahoo Finance
Jasper reports promising early results in urticaria study - Investing.com
Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday? - Benzinga
Jasper Therapeutics Stock Gains on Strong Briquilimab Trial Results - MarketWatch
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria - GlobeNewswire
Jasper reports promising early results in urticaria study By Investing.com - Investing.com UK
American Century Companies Inc. Has $320,000 Stock Holdings in Arcos Dorados Holdings Inc. (NYSE:ARCO) - Defense World
American Century Companies Inc. Grows Position in Hippo Holdings Inc. (NYSE:HIPO) - Defense World
Novavax (NASDAQ:NVAX) versus Jasper Therapeutics (NASDAQ:JSPR) Critical Contrast - Defense World
Jasper Therapeutics' SWOT analysis: briquilimab's potential in mast cell diseases - Investing.com India
Oppenheimer maintains Outperform rating on Jasper Therapeutics shares By Investing.com - Investing.com Canada
8,750 Shares in Sunrun Inc. (NASDAQ:RUN) Bought by Point72 Asia Singapore Pte. Ltd. - Defense World
Susquehanna Fundamental Investments LLC Invests $23.60 Million in Light & Wonder, Inc. (NASDAQ:LNW) - Defense World
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):